Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
$15.17
-$0.39(-4.51%)
At close: 4:00 PM EST
$15.17
-$0.39(-4.51%)
Day’s Range― - ―
52-Week Range$7.30 - $17.30
Previous CloseN/A
Volume49.40K
Average Volume (3M)1.37M
Market Cap
$766.79M
Enterprise ValueN/A
Total Cash (Recent Filing)$309.16M
Total Debt (Recent Filing)$149.59M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Dec 04, 2025EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,546,290
10 Day Avg. Volume1,007,669
30 Day Avg. Volume1,372,303
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)7.17
Price to Sales (P/S)0.00
P/FCF Ratio-4.47
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$32.13Price Target Upside111.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.27
Revenue Forecast (FY)$34.45M
Bulls Say, Bears Say
Bulls Say
Market PenetrationEkterly has already penetrated the market by approximately 10% in a few short months and will have the opportunity to entrench itself further prior to PHVS entry more than a year from now.
Patient AdoptionThe combination of early physician adoption, wide patient penetration, active payer talks, and forthcoming catalysts positions Ekterly for sustained uptake and category leadership.
Sales PerformanceEkterly revenue hit $13.7mn in 3Q, significantly surpassing both FactSet consensus and analyst estimates.
Bears Say
Competitive ConcernsThe main open question is whether the magnitude of benefit will be sufficient to drive significant switching among Ekterly users.
Market ReactionStock reaction was relatively muted as visibility into organic revenue remains limited due to no numerical detail on inventory contribution or payor KPIs.
Trial OverhangKALV shares reaction is muted which is attributed to the overhang of the imminent phase 3 trial readout of Pharvaris' deucrictibant.
KalVista Pharmaceuticals News
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $17.30 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $766.79M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Dec 04, 2025 which is 24 days ago.
How were KalVista Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -1.05.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 50,546,290 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.13 (111.80% Upside)
$32.13 (111.80% Upside)
Blogger Sentiment
Neutral
KALV Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighting significant achievements such as the FDA approval and successful early launch of EKTERLY, strong patient and prescriber engagement, and positive regulatory progress in Europe. However, challenges remain with high operating expenses and potential reimbursement hurdles with certain insurers.View all KALV earnings summariesKALV Stock 12 Month Forecast
Average Price Target
$32.13
▲(111.80% Upside)
Technical Analysis
Savara
―
Arvinas Holding Company
―
Gossamer Bio
―
Compass Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---